| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Common Stock | Award | +994 | +67.67% | 2.46K | May 18, 2021 | Direct | F1, F2, F3 | ||
| transaction | HAE | Common Stock | Sale | -$2.32K | -42 | -1.71% | $55.19 | 2.42K | May 19, 2021 | Direct | F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Non-qualified Stock Option (Right to Buy) | Award | $0 | +2.69K | $0.00 | 2.69K | May 18, 2021 | Common Stock | 2.69K | $56.57 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. |
| F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
| F3 | This number includes unvested RSUs previously reported. |
| F4 | Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| F5 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |